Prolonged Anti-tumor Activity of Lucitanib in Advanced Thyroid CancerCapdevila · Annals of Oncology2014PDF33 KB
3032A Activity and Safety Profile of Lucitanib in Patients with Advanced Thymic Epithelial TumoursBesse · European Journal of Cancer2015PDF62 KB
Phase I/iia Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lucitanib in Advanced Solid TumorsSoria · Annals of Oncology2014PDF871 KB
In Vitro and in Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer ModelsGuffanti · Neoplasia2017PDF946 KB
A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal CarcinomaZhang · The Oncologist2022PDF13 MB
Corrections to “phase I/iia Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lucitanib in Advanced Solid Tumors”Soria · Annals of Oncology2015PDF38 KB
Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE StudyHui · American Association for Cancer Research Inc.2020PDF1.2 MB
340 Preclinical Activity of the Vegfr, FGFR and PDGFR Inhibitor Lucitanib in FGFR2 Aberrant Endometrial and Gastric Cancer ModelsGuffanti · European Journal of Cancer2014PDF60 KB
Lucitanib for the Treatment of Hr+ HER2- Metastatic Breast Cancer (mbc) Patients (pts): Results from the Multicohort Phase II FINESSE TrialHui · Annals of Oncology2018PDF81 KB
268MO a Phase-ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma (npc)Zhao · Annals of Oncology2020PDF103 KB
Initial Clinical Experience of Lucitanib + Nivolumab in Advanced Metastatic Solid Tumours: Data from the Phase Ib/ii LIO-1 Study (CO-3810-101; NCT04042116)Hamilton · Annals of Oncology2020PDF94 KB
885TiP LIO-1: A Phase II Study of Lucitanib + Nivolumab in Patients (pts) with Gynaecological Tumours (CO-3810-101; NCT04042116; ENGOT-GYN3/AGO/LIO)Concin · Annals of Oncology2020PDF69 KB
